BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28082416)

  • 1. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.
    Sun Y; Alberta JA; Pilarz C; Calligaris D; Chadwick EJ; Ramkissoon SH; Ramkissoon LA; Garcia VM; Mazzola E; Goumnerova L; Kane M; Yao Z; Kieran MW; Ligon KL; Hahn WC; Garraway LA; Rosen N; Gray NS; Agar NY; Buhrlage SJ; Segal RA; Stiles CD
    Neuro Oncol; 2017 Jun; 19(6):774-785. PubMed ID: 28082416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.
    Sievert AJ; Lang SS; Boucher KL; Madsen PJ; Slaunwhite E; Choudhari N; Kellet M; Storm PB; Resnick AC
    Proc Natl Acad Sci U S A; 2013 Apr; 110(15):5957-62. PubMed ID: 23533272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
    Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups.
    Kurani H; Gurav M; Shetty O; Chinnaswamy G; Moiyadi A; Gupta T; Jalali R; Epari S
    Childs Nerv Syst; 2019 Sep; 35(9):1525-1536. PubMed ID: 31321520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIAA1549:BRAF fusion gene in pediatric brain tumors of various histogenesis.
    Antonelli M; Badiali M; Moi L; Buttarelli FR; Baldi C; Massimino M; Sanson M; Giangaspero F
    Pediatr Blood Cancer; 2015 Apr; 62(4):724-7. PubMed ID: 25382612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
    Tian Y; Rich BE; Vena N; Craig JM; Macconaill LE; Rajaram V; Goldman S; Taha H; Mahmoud M; Ozek M; Sav A; Longtine JA; Lindeman NI; Garraway LA; Ligon AH; Stiles CD; Santagata S; Chan JA; Kieran MW; Ligon KL
    J Mol Diagn; 2011 Nov; 13(6):669-77. PubMed ID: 21884820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RAF dimers: it takes two to tango.
    Cook FA; Cook SJ
    Biochem Soc Trans; 2021 Feb; 49(1):237-251. PubMed ID: 33367512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for BRAFV600E malignant astrocytoma.
    Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
    Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
    Selt F; Hohloch J; Hielscher T; Sahm F; Capper D; Korshunov A; Usta D; Brabetz S; Ridinger J; Ecker J; Oehme I; Gronych J; Marquardt V; Pauck D; Bächli H; Stiles CD; von Deimling A; Remke M; Schuhmann MU; Pfister SM; Brummer T; Jones DT; Witt O; Milde T
    Oncotarget; 2017 Feb; 8(7):11460-11479. PubMed ID: 28002790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
    Huillard E; Hashizume R; Phillips JJ; Griveau A; Ihrie RA; Aoki Y; Nicolaides T; Perry A; Waldman T; McMahon M; Weiss WA; Petritsch C; James CD; Rowitch DH
    Proc Natl Acad Sci U S A; 2012 May; 109(22):8710-5. PubMed ID: 22586120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel GIT2-BRAF fusion in pilocytic astrocytoma.
    Helgager J; Lidov HG; Mahadevan NR; Kieran MW; Ligon KL; Alexandrescu S
    Diagn Pathol; 2017 Nov; 12(1):82. PubMed ID: 29141672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BRAF in pediatric brain tumors.
    Kieran MW
    Am Soc Clin Oncol Educ Book; 2014; ():e436-40. PubMed ID: 24857135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of disseminated pilocytic astrocytomas.
    Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects.
    Kaul A; Chen YH; Emnett RJ; Gianino SM; Gutmann DH
    Genesis; 2013 Oct; 51(10):708-16. PubMed ID: 23893969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel RAF Fusions in Pediatric Low-Grade Gliomas Demonstrate MAPK Pathway Activation.
    Lind KT; Chatwin HV; DeSisto J; Coleman P; Sanford B; Donson AM; Davies KD; Willard N; Ewing CA; Knox AJ; Mulcahy Levy JM; Gilani A; Green AL
    J Neuropathol Exp Neurol; 2021 Dec; 80(12):1099-1107. PubMed ID: 34850053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.
    Becker AP; Scapulatempo-Neto C; Carloni AC; Paulino A; Sheren J; Aisner DL; Musselwhite E; Clara C; Machado HR; Oliveira RS; Neder L; Varella-Garcia M; Reis RM
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):743-54. PubMed ID: 26083571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.
    Waizenegger IC; Baum A; Steurer S; Stadtmüller H; Bader G; Schaaf O; Garin-Chesa P; Schlattl A; Schweifer N; Haslinger C; Colbatzky F; Mousa S; Kalkuhl A; Kraut N; Adolf GR
    Mol Cancer Ther; 2016 Mar; 15(3):354-65. PubMed ID: 26916115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of BRAF dimers using an allosteric site.
    Cotto-Rios XM; Agianian B; Gitego N; Zacharioudakis E; Giricz O; Wu Y; Zou Y; Verma A; Poulikakos PI; Gavathiotis E
    Nat Commun; 2020 Sep; 11(1):4370. PubMed ID: 32873792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.